Substituted imidazo[1,2-d]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus infections

摘要

The present invention relates to compounds of formula (I);
its salts, isomers or prodrugs thereof useful in the treatment of viral infections, in particular respiratory syncytial virus (RSV) infections. The present invention also relates to processes for preparing the compounds and intermediates used in their preparation.

主权项

1. A compound of formula (I): wherein represents single or double bonds depending on the required valencies of the ring atoms; each Y is independently selected from the group consisting of CH2 and CH; X is CH; X1 is selected from the group consisting of O, S, NR6 and C(R6)2, wherein R6 is independently selected from the group consisting of H, optionally substituted C1-6alkyl, optionally substituted C2-6alkenyl, optionally substituted C2-6alkynyl, optionally substituted C3-8cycloalkyl, optionally substituted heterocyclyl and optionally substituted aryl; X2 is C(R3)(R4), wherein R3 and R4 are independently selected from the group consisting of H, optionally substituted C1-6alkyl, optionally substituted C2-6alkenyl, optionally substituted C2-6alkynyl, optionally substituted C3-8cycloalkyl, optionally substituted heterocyclyl and optionally substituted aryl; R1 is selected from the group consisting of optionally substituted C1-6alkyl, optionally substituted C2-6alkenyl, optionally substituted C2-6alkynyl, optionally substituted C3-8cycloalkyl, optionally substituted heterocyclyl and optionally substituted aryl; R2 is selected from the group consisting of H, R8, C(═O)R8, C(═S)R8 and S(O)2R8, wherein R8 is selected from the group consisting of optionally substituted C1-6alkyl, optionally substituted C2-6alkenyl, optionally substituted C2-6alkynyl, N(R6)2, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted —N(R6)q(R7)qcycloalkyl, optionally substituted —N(R6)q(R7)qheterocyclyl and optionally substituted —N(R6)q(R7)qaryl; each R7 is independently selected from the group consisting of optionally substituted C1-6alkyl, optionally substituted C2-6alkenyl, optionally substituted C2-6alkynyl, optionally substituted C3-8cycloalkyl, optionally substituted heterocyclyl and optionally substituted aryl; each q is independently 0 or 1; Y1 is one or more substituents independently selected from the group consisting of R7, R7—R7, (R7)qhalo, (R7)qCN, ═O, (R7)qOR6, (R7)qOCHF2, (R7)qOCF3, (R7)qCHF2, (R7)qCF3, ═S, (R7)qSR6, (R7)qSO3H, (R7)qS(O)2—R7, (R7)qS(O)2—N(R6)2, (R7)qNO2, (R7)qN(R6)2, (R7)qOC(═O)—R7, (R7)qC(═O)—OR6, (R7)qC(═O)—R6, (R7)qC(═O)—N(R6)2, (R7)qNR6C(═O)—R7, (R7)qNR6—S(O)2—R7 and (R7)qSi(R7)3; or Y1 is absent; Y2 is H or one or more optionally substituted R7; or Y2 is absent; m is 1; n is 1; and p is 2; wherein the optional substituents are independently selected from the group consisting of R7, R7—R7, (R7)qhalo, (R7)qCN, ═O, (R7)qOR6, (R7)qOCHF2, (R7)qOCF3, (R7)qCHF2, (R7)qCF3, ═S, (R7)qSR6, (R7)qSO3H, (R7)qS(O)2—R7, (R7)qS(O)2—N(R6)2, (R7)qNO2, (R7)qN(R6)2, (R7)qC(═O)—R7, (R7)qC(═O)—OR6, (R7)qC(═O)—R6, (R7)qC(═O)—N(R6)2, (R7)qNR6C(═O)—R7, (R7)qNR6—S(O)2—R7, (R7)qSi(R7)3 and (R7)qOSi(R7)3; or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof.